Our earlier report suggested that the presence of SLC28A2 + 65 CC/CT SNP may increase the sensitivity to gemcitabine and thus giving NSCLC patients a better prognosis [12]. The gene discussed is SLC28A2; the disease is non-small cell lung carcinoma.